BELLEVILLE, ON, July 10 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
presented data regarding its E. coli O157:H7 cattle vaccine at the XXV World
Buiatrics Congress in Budapest, Hungary today. The presentation was made by
Dr. Dragan Rogan, Vice-President, Bioniche Animal Health Research &
Development. It was entitled, "Vaccination of Cattle with E. coli O157:H7 Type
III Secretion Proteins as a Pre-Slaughter Intervention Method to Reduce E.
coli O157:H7 Prevalence", and was co-authored by Dr. David Smith, Dr. Rod
Moxley, Dr. Andy Potter and Julie Yome.
The World Buiatrics Congress is the largest event of its kind in the
cattle industry, and is attended by scientists from universities and research
institutes, practitioners working with dairy and beef cattle and other
ruminants, consultants, post-docs, PhDs and graduate students of veterinary
medicine and animal science from around the world.
The Bioniche vaccine is the world's first vaccine that may be used as an
on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle.
Bioniche and its collaborators have been moving the vaccine towards commercial
availability for eight years and it has been extensively tested at the
University Nebraska-Lincoln, with efficacy results now being published in
peer-reviewed scientific journals, most recently, the Journal of Food
Protection, in November, 2007.
In his presentation in Budapest, Dr. Rogan summarized numerous studies
that have been completed with the Bioniche vaccine over the last five years
involving more than 30,000 cattle. In one study, calves were vaccinated with
three doses and challenged with E. coli O157:H7 14 days later. There was a
2.28 log10 reduction in the magnitude of shedding in vaccinated animals
compared to controls. In another study, with a three-dose vaccination and
natural exposure to E. coli O157:H7, vaccinated animals were less likely to be
colonized by the bacteria in the mucosa of the terminal rectum at harvest
(OR=0.014, p(less than)0.0001), resulting in a vaccine colonization efficacy
of 98.3%. A two-dose vaccination was used to evaluate hide contamination in
the feedlot. Hides were sampled for E. coli O157:H7 contamination twice in the
feedlot and immediately before and after animals were shipped to the abattoir.
This same study also found a statistically significant reduction in the
likelihood of vaccinated animals having contaminated hides. Additionally,
pen-level prevalence following a two dose vaccination was assessed in a
feedlot study. Vaccinated pens were less likely than unvaccinated pens to test
positive (OR=0.59, p(less than)0.004) using the ROPES method.
"These results provide compelling evidence that vaccination of cattle
with the Bioniche E. coli O157:H7 cattle vaccine has the potential to be an
effective pre-slaughter intervention for the reduction of E. coli O157:H7
shedding, colonization, hide contamination, and pen-level prevalence,"
concluded Dr. Rogan.
Food recalls due to E. coli O157:H7 contamination continue to be a
concern in beef, produce and prepared food. On-farm interventions to reduce
the shedding of E. coli O157:H7 by cattle, such as vaccination, may assist in
reducing the potential for food and water contamination and the resulting
human illnesses and deaths.
Approximately 100,000 cases of human infection with the E. coli O157:H7
organism are reported each year in North America. 2% to 7% of those people
develop hemolytic uremic syndrome (HUS), a disease characterized by kidney
failure (in recent outbreaks, this percentage has risen to as high as 16%).
Five percent of HUS patients die, many of them children and senior citizens,
whose kidneys are more sensitive to damage.
In addition to being infected by contaminated food or water, individuals
can become infected from E. coli O157:H7 by visiting animal exhibits. Petting
zoos, fairs, and agricultural exhibits provide many possible routes of
transmission for E. coli. Direct animal contact is the obvious route, but
contact with contaminated products (e.g., sawdust, shavings, soiled clothing
or shoes) can also lead to human infection.
The E. coli O157:H7 cattle vaccine will be manufactured in the Bioniche
production facility in Belleville, Ontario, Canada where a two-year,
$25 million expansion is taking place, supported by the Ontario and Canadian
governments. Vaccine supply will be limited during this manufacturing
About the E. coli O157:H7 Cattle Vaccine
This vaccine received international recognition in September, 2007 by the
Animal Pharm Industry Excellence Awards as the best new veterinary product for
livestock globally. The vaccine has been developed by a strategic alliance
formed in 2000 between the University of British Columbia (UBC), the Alberta
Research Council (ARC), the University of Saskatchewan's Vaccine & Infectious
Disease Organization (VIDO), and Bioniche, which holds the rights for
worldwide commercialization of the vaccine. The vaccine prevents the E. coli
O157:H7 bacteria from attaching to the intestines of vaccinated cattle,
thereby reducing their reproduction within the animal, and reducing the amount
of bacteria that can be released through cattle manure in the environment.
More than 30,000 cattle have been involved in clinical testing of the vaccine
over the past five years.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of Canada's Top Ten Life Sciences
Companies for 2008. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Jennifer Shea, Corporate Communications,
Investor & Government Relations Director, Bioniche Life Sciences Inc.,
Telephone: (613) 966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com